SG10201603766PA - 4 - pregenen- 11ss - 17 - 21 -triol-3, 20 -dione derivatives for the treatment of ocular conditions - Google Patents

4 - pregenen- 11ss - 17 - 21 -triol-3, 20 -dione derivatives for the treatment of ocular conditions

Info

Publication number
SG10201603766PA
SG10201603766PA SG10201603766PA SG10201603766PA SG10201603766PA SG 10201603766P A SG10201603766P A SG 10201603766PA SG 10201603766P A SG10201603766P A SG 10201603766PA SG 10201603766P A SG10201603766P A SG 10201603766PA SG 10201603766P A SG10201603766P A SG 10201603766PA
Authority
SG
Singapore
Prior art keywords
pregenen
triol
treatment
dione derivatives
ocular conditions
Prior art date
Application number
SG10201603766PA
Other languages
English (en)
Inventor
Jeffrey L Edelman
Alissar Nehme
Thomas C Malone
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47179019&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201603766P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of SG10201603766PA publication Critical patent/SG10201603766PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG10201603766PA 2011-11-11 2012-11-09 4 - pregenen- 11ss - 17 - 21 -triol-3, 20 -dione derivatives for the treatment of ocular conditions SG10201603766PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161558775P 2011-11-11 2011-11-11

Publications (1)

Publication Number Publication Date
SG10201603766PA true SG10201603766PA (en) 2016-07-28

Family

ID=47179019

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201603766PA SG10201603766PA (en) 2011-11-11 2012-11-09 4 - pregenen- 11ss - 17 - 21 -triol-3, 20 -dione derivatives for the treatment of ocular conditions
SG11201402247PA SG11201402247PA (en) 2011-11-11 2012-11-09 4 - pregenen- 11ss - 17 - 21 -triol-3, 20 -dione derivatives for the treatment of ocular conditions
SG11201402225RA SG11201402225RA (en) 2011-11-11 2012-11-09 PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF 4-PREGENEN-11ß-17-21-TRIOL-3,20-DIONE DERIVATIVES

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG11201402247PA SG11201402247PA (en) 2011-11-11 2012-11-09 4 - pregenen- 11ss - 17 - 21 -triol-3, 20 -dione derivatives for the treatment of ocular conditions
SG11201402225RA SG11201402225RA (en) 2011-11-11 2012-11-09 PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF 4-PREGENEN-11ß-17-21-TRIOL-3,20-DIONE DERIVATIVES

Country Status (24)

Country Link
US (7) US8865691B2 (zh)
EP (2) EP2776040B1 (zh)
JP (2) JP6158201B2 (zh)
KR (2) KR20140095549A (zh)
CN (2) CN104203247B (zh)
AR (1) AR088846A1 (zh)
AU (3) AU2012335590B2 (zh)
BR (2) BR112014011341A2 (zh)
CA (3) CA2855929C (zh)
CL (2) CL2014001244A1 (zh)
CO (2) CO6970598A2 (zh)
ES (1) ES2806603T3 (zh)
HK (2) HK1200367A1 (zh)
IL (2) IL232535B (zh)
IN (2) IN2014CN03903A (zh)
MX (3) MX365859B (zh)
MY (2) MY172227A (zh)
PH (2) PH12014501079B1 (zh)
RU (2) RU2688159C2 (zh)
SG (3) SG10201603766PA (zh)
TW (1) TWI584809B (zh)
UA (2) UA111867C2 (zh)
WO (2) WO2013071009A1 (zh)
ZA (2) ZA201403431B (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
UA111867C2 (uk) 2011-11-11 2016-06-24 Аллерган, Інк. ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ І СПОСІБ ЗАСТОСУВАННЯ ПОХІДНИХ 4-ПРЕГНЕН-11β-17-21-ТРІОЛ-3,20-ДІОНУ
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EA201500651A1 (ru) 2012-12-18 2015-11-30 Альмираль, С.А. НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛ- И ХИНУКЛИДИНИЛКАРБАМАТА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
AR098747A1 (es) * 2013-12-13 2016-06-08 Allergan Inc Formas polimórficas de un compuesto similar a esteroides y métodos para su preparación y uso
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
RU2746083C2 (ru) * 2015-03-05 2021-04-06 Аллерган, Инк. Самоэмульгирующиеся системы доставки лекарств (sedds) для доставки офтальмологического лекарства
CA3037176A1 (en) * 2016-09-16 2018-03-22 Kala Pharmaceuticals, Inc. Particles, compositions, and methods for ophthalmic and/or other applications
WO2019055028A1 (en) * 2017-09-15 2019-03-21 Kala Pharmaceuticals, Inc. PARTICLES, COMPOSITIONS AND METHODS FOR OPHTHALMIC APPLICATIONS AND / OR OTHER APPLICATIONS
CN116023425B (zh) * 2023-03-28 2023-06-20 南京师范大学 曲安西龙衍生物及其医药用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6605514A (zh) * 1966-04-25 1967-10-26
IT1056711B (it) * 1967-04-01 1982-02-20 Vismara F Spa Derivati dell idrocortisone
US3484436A (en) * 1967-09-07 1969-12-16 Syntex Corp Bicyclo(2.2.2)octane - 1 - -carboxylate esters of delta**4 - pregnene corticoid steroids
GB1227992A (zh) 1968-01-23 1971-04-15 Koninklijke Gist Spiritus
US3693032A (en) 1971-04-23 1972-09-19 Ibm Antisaturation technique for ttl circuits
US3984544A (en) * 1975-02-28 1976-10-05 Schering Corporation Retinoic acid esters of steroids of the pregnane series, their use in the treatment of acne and pharmaceutical formulations useful therefor
JPS52136157A (en) * 1976-04-14 1977-11-14 Taisho Pharmaceut Co Ltd Preparation of steroid 17-esters
JPS60994B2 (ja) * 1976-07-26 1985-01-11 大正製薬株式会社 プレグナン系化合物の１７α―エステル類の製造法
DE2735110A1 (de) * 1977-08-04 1979-02-15 Hoechst Ag Corticoid-17-alkylcarbonate und verfahren zu ihrer herstellung
US4221787A (en) * 1978-03-28 1980-09-09 Interx Research Corporation Esteramide prodrugs of anti-inflammatory corticosteroids
US4221778A (en) * 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
DE4025342A1 (de) 1990-08-10 1992-02-13 Hoechst Ag In 17-stellung substituierte corticoid-17-alkylcarbonate, verfahren zu deren herstellung und diese enthaltende arzneimittel
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
CN1157404C (zh) * 1999-10-15 2004-07-14 里奥药物制品有限公司 新的梭链孢酸衍生物
US6395721B1 (en) 2000-01-05 2002-05-28 Leonard Bloom Low potency unpreserved sterile topical corticosteroid compositions for dermatitis
JP4619786B2 (ja) * 2002-08-29 2011-01-26 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 炎症性、アレルギー性及び増殖性疾患の治療において糖質コルチコイドミメティックスとして使用するための３−（スルホンアミドエチル）−インドール誘導体
JP2005008596A (ja) * 2003-06-20 2005-01-13 Kobayashi Pharmaceut Co Ltd 眼科用組成物
CA2562356A1 (en) * 2004-04-08 2005-10-27 Retmed Pty Ltd Treatment of ophthalmic conditions with mineralcorticoids
WO2006017347A2 (en) * 2004-07-12 2006-02-16 Allergan, Inc. Opthalmic compositions and methods for treating ophthalmic conditions
US7687484B2 (en) * 2006-05-25 2010-03-30 Bodor Nicholas S Transporter enhanced corticosteroid activity
US7691811B2 (en) * 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
EP2319517B1 (en) * 2006-06-01 2013-09-11 Novagali Pharma S.A. Use of prodrugs for ocular intravitreous administration
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
JP2009053880A (ja) 2007-08-27 2009-03-12 Sony Broadband Solution Corp 情報処理装置、ならびにｃｐｕユニット
AR069804A1 (es) * 2007-12-21 2010-02-17 Schering Corp Agonistas del receptor glucocorticoide c20- c21 sustituido
CN105147608B (zh) * 2008-06-26 2019-12-10 安特里奥公司 真皮递送
UA111867C2 (uk) 2011-11-11 2016-06-24 Аллерган, Інк. ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ І СПОСІБ ЗАСТОСУВАННЯ ПОХІДНИХ 4-ПРЕГНЕН-11β-17-21-ТРІОЛ-3,20-ДІОНУ

Also Published As

Publication number Publication date
CA2855929C (en) 2018-03-27
PH12014501079A1 (en) 2014-07-28
JP2014533274A (ja) 2014-12-11
CL2014001243A1 (es) 2014-11-28
US8906892B2 (en) 2014-12-09
PH12014501078A1 (en) 2014-07-28
AU2018200436A1 (en) 2018-02-08
AU2012335590A1 (en) 2014-05-29
CA2855290C (en) 2017-02-28
US8865691B2 (en) 2014-10-21
JP6216719B2 (ja) 2017-10-18
NZ624920A (en) 2017-06-30
SG11201402225RA (en) 2014-06-27
US20130123226A1 (en) 2013-05-16
EP2776040A1 (en) 2014-09-17
AU2018200436B2 (en) 2019-10-24
CN104203247B (zh) 2017-06-06
MX2014005679A (es) 2014-12-10
MX2019006877A (es) 2019-08-22
KR20140095548A (ko) 2014-08-01
ZA201403430B (en) 2016-05-25
US20170182062A1 (en) 2017-06-29
JP2014533275A (ja) 2014-12-11
HK1200367A1 (zh) 2015-08-07
CA2855290A1 (en) 2013-05-16
SG11201402247PA (en) 2014-06-27
WO2013071009A1 (en) 2013-05-16
MX365859B (es) 2019-06-18
CL2014001244A1 (es) 2014-11-14
AU2012335590B2 (en) 2017-10-19
HK1200366A1 (zh) 2015-08-07
ZA201403431B (en) 2016-05-25
US20150005519A1 (en) 2015-01-01
IN2014CN03919A (zh) 2015-09-04
CA2991883A1 (en) 2013-05-16
WO2013071010A1 (en) 2013-05-16
RU2683775C2 (ru) 2019-04-02
IN2014CN03903A (zh) 2015-10-16
AR088846A1 (es) 2014-07-10
EP2776041A1 (en) 2014-09-17
UA111867C2 (uk) 2016-06-24
PH12014501078B1 (en) 2014-07-28
KR20140095549A (ko) 2014-08-01
IL232535A0 (en) 2014-06-30
US20130123223A1 (en) 2013-05-16
MX363669B (es) 2019-03-29
MY182222A (en) 2021-01-18
UA116622C2 (uk) 2018-04-25
MY172227A (en) 2019-11-18
CN104185472A (zh) 2014-12-03
JP6158201B2 (ja) 2017-07-05
IL232534A0 (en) 2014-06-30
BR112014011333A2 (pt) 2017-05-02
KR102049615B1 (ko) 2019-11-28
AU2012335589B2 (en) 2017-08-31
TW201325596A (zh) 2013-07-01
CA2991883C (en) 2020-03-10
US10493082B2 (en) 2019-12-03
EP2776040B1 (en) 2020-04-22
US20190365786A1 (en) 2019-12-05
CN104185472B (zh) 2017-06-13
RU2014123471A (ru) 2015-12-20
AU2012335589A1 (en) 2014-05-29
CO6970609A2 (es) 2014-06-13
MX2014005678A (es) 2014-12-10
IL232535B (en) 2019-09-26
ES2806603T3 (es) 2021-02-18
CN104203247A (zh) 2014-12-10
PH12014501079B1 (en) 2014-07-28
CO6970598A2 (es) 2014-06-13
US10188667B2 (en) 2019-01-29
NZ624919A (en) 2016-10-28
RU2688159C2 (ru) 2019-05-20
US20180147217A1 (en) 2018-05-31
BR112014011333B1 (pt) 2020-04-28
CA2855929A1 (en) 2013-05-16
US9433631B2 (en) 2016-09-06
TWI584809B (zh) 2017-06-01
BR112014011341A2 (pt) 2017-05-02
US20150057258A1 (en) 2015-02-26
US9717743B2 (en) 2017-08-01
RU2014123472A (ru) 2015-12-20

Similar Documents

Publication Publication Date Title
HUS1900040I1 (hu) Makrociklusos származékok proliferatív betegségek kezelésére
HK1200367A1 (zh) 用於治療眼部疾病的 -孕甾烯- -三醇- -二酮衍生物
ZA201405820B (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
HK1197400A1 (zh) 治療 的化合物
IL230830A0 (en) Cellular preparations for the treatment of degenerative diseases of the retina
HK1201196A1 (zh) 眼病的治療
EP2670439A4 (en) ACTIVE PRINCIPLE TO ATTENUATE ADVERSE MEDICAL DISORDERS
IL230635A (en) An outgrowth of 4,3,2,1-tetrahydroquinoline used to treat diabetes
EP2671586A4 (en) PHARMACOTHERAPY FOR THE PREVENTION OR TREATMENT OF GLAUCOMA
EP2882387A4 (en) EYE NECKLACE STENT FOR TREATING IRIDO-CORNEAN ANGLE SHRINKAGE
SG2014014724A (en) METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
IL230960A0 (en) A device for the treatment of eye disease
ZA201403736B (en) Process for the preparation of sterol derivatives
ZA201306613B (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
PL2538918T3 (pl) Cytocholina do leczenia jaskry
IL230959B (en) A device for the treatment of eye disease
HK1208454A1 (zh) 治療細菌性疾病的嘧啶衍生物
EP2701702A4 (en) OXYMETAZOLINE FOR THE TREATMENT OF ANO-RECTAL DISEASES
PL395469A1 (pl) Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego
PT2777699T (pt) Dietilamina-2,5-di-hidroxibenzenossulfonato para o tratamento de degeneração macular relacionada com a idade
IL228973A (en) Oxymetazoline for the treatment of rectal disorders
EP2696872A4 (en) TREATMENT OF GLAUCOMA
GB201108301D0 (en) IVlg treatment for patients with Myeloma
AU2011903756A0 (en) Orifice treatment means
AU2011903969A0 (en) Compositions for treating skin conditions